JP5891230B2 - 細菌性髄膜炎の治療方法 - Google Patents

細菌性髄膜炎の治療方法 Download PDF

Info

Publication number
JP5891230B2
JP5891230B2 JP2013529664A JP2013529664A JP5891230B2 JP 5891230 B2 JP5891230 B2 JP 5891230B2 JP 2013529664 A JP2013529664 A JP 2013529664A JP 2013529664 A JP2013529664 A JP 2013529664A JP 5891230 B2 JP5891230 B2 JP 5891230B2
Authority
JP
Japan
Prior art keywords
hbp
individual
meningitis
bacterial meningitis
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013529664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543581A (ja
JP2013543581A5 (https=
Inventor
ビエルク、ラルス
クリステンソン、ベルティル
ハーヴァルト、ヘイコ
リンデル、アダム
オケソン、ペル
Original Assignee
ハンサ メディカル アクチボラゲット
ハンサ メディカル アクチボラゲット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハンサ メディカル アクチボラゲット, ハンサ メディカル アクチボラゲット filed Critical ハンサ メディカル アクチボラゲット
Publication of JP2013543581A publication Critical patent/JP2013543581A/ja
Publication of JP2013543581A5 publication Critical patent/JP2013543581A5/ja
Application granted granted Critical
Publication of JP5891230B2 publication Critical patent/JP5891230B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4721—Cationic antimicrobial peptides, e.g. defensins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2013529664A 2010-09-24 2011-09-23 細菌性髄膜炎の治療方法 Active JP5891230B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1016161.0A GB201016161D0 (en) 2010-09-24 2010-09-24 Diagnostic method
GB1016161.0 2010-09-24
PCT/EP2011/066611 WO2012038541A1 (en) 2010-09-24 2011-09-23 Diagnostic method for bacterial meningitis

Publications (3)

Publication Number Publication Date
JP2013543581A JP2013543581A (ja) 2013-12-05
JP2013543581A5 JP2013543581A5 (https=) 2014-10-02
JP5891230B2 true JP5891230B2 (ja) 2016-03-22

Family

ID=43127976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013529664A Active JP5891230B2 (ja) 2010-09-24 2011-09-23 細菌性髄膜炎の治療方法

Country Status (6)

Country Link
US (1) US9759720B2 (https=)
EP (1) EP2619583B1 (https=)
JP (1) JP5891230B2 (https=)
CN (1) CN103250054B (https=)
GB (1) GB201016161D0 (https=)
WO (1) WO2012038541A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
GB201016161D0 (en) 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
GB201102108D0 (en) 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method
GB201518597D0 (en) * 2015-10-20 2015-12-02 Univ Liverpool Detection of bacterial infection
US11287396B2 (en) 2020-06-05 2022-03-29 Princeton Biochemicals, Inc. Method and system for simultaneous determination of multiple measurable biomarkers during the development of a communicable disease
CN111951963B (zh) 2020-07-30 2022-09-02 中翰盛泰生物技术股份有限公司 Hbp在covid-19患者的预后风险预警中的应用
CN111951969A (zh) * 2020-08-05 2020-11-17 中翰盛泰生物技术股份有限公司 Hbp在高危妊娠预测中的应用
CN121513038A (zh) * 2026-01-16 2026-02-13 湖北工业大学 包含舒洛地特和头孢曲松的组合物在制备治疗细菌性脑膜炎的药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
US5962241A (en) 1989-07-28 1999-10-05 The University Of Arizona Monoclonal antibody detection of proteins on sperm related to fertility
US5314804A (en) 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
RU2200573C2 (ru) * 1994-04-21 2003-03-20 Леукотех А/С Связывающий гепарин белок для лечения сепсиса
US5976536A (en) * 1995-08-09 1999-11-02 Emory University Neisseria mutants, lipooligosaccharides and immunogenic compositions
US5778895A (en) 1997-01-29 1998-07-14 Uab Research Foundation Method of discriminating bacterial from aseptic meningitis
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
AU2003220034A1 (en) 2002-03-08 2003-09-22 Heloise, Anne, Pereira, Ph. D. An early detection marker for chronic inflammatory associated diseases
US7655480B2 (en) 2002-03-08 2010-02-02 The Board Of Regents Of The University Of Oklahoma Method for predicting sepsis or an acute infectious inflammatory response
WO2004016653A2 (en) 2002-08-15 2004-02-26 Leukotech A/S Bactericidal, anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp) or human neutrophil elastase
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
EP1638530A2 (en) 2003-06-20 2006-03-29 Royer Biomedical, INC. Drug polymer complexes
WO2005028512A1 (en) 2003-09-19 2005-03-31 Leukotech A/S Pro-inflammatory and anti-inflammatory antibodies against the heparin-binding protein (hbp)
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
CA2605143A1 (en) 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
WO2007041623A2 (en) 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
GB0521276D0 (en) 2005-10-19 2005-11-30 Lewitt Moira S Medical uses and therapies based upon the action of azurocidin on IGFBP-1
FR2894675B1 (fr) 2005-12-14 2008-06-27 Assist Publ Hopitaux De Paris Distinction des meningites bacteriennes et virales
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
GB201016161D0 (en) 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
GB201102108D0 (en) 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method

Also Published As

Publication number Publication date
WO2012038541A1 (en) 2012-03-29
GB201016161D0 (en) 2010-11-10
JP2013543581A (ja) 2013-12-05
CN103250054A (zh) 2013-08-14
CN103250054B (zh) 2015-06-17
US9759720B2 (en) 2017-09-12
US20140080754A1 (en) 2014-03-20
EP2619583B1 (en) 2014-10-29
EP2619583A1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
JP5891230B2 (ja) 細菌性髄膜炎の治療方法
Tengnér et al. Detection of anti‐Ro/SSA and anti‐La/SSB autoantibody‐producing cells in salivary glands from patients with Sjögren's syndrome
Mussap et al. Soluble CD14 subtype (sCD14-ST) presepsin in premature and full term critically ill newborns with sepsis and SIRS
US20230051905A1 (en) Triaging method using cell free nucleosome levels
JP5818916B2 (ja) 尿路感染症の診断方法
CA2690067A1 (en) A diagnostic method by measuring the levels of heparin-binding protein
Nie et al. Multiplexed salivary protein profiling for patients with respiratory diseases using fiber-optic bundles and fluorescent antibody-based microarrays
CN104285148B (zh) 检测弥散性血管内凝血或感染性弥散性血管内凝血的方法
WO2021117044A1 (en) Non-invasive assay for differentiating between bacterial and viral infections
WO2016161413A1 (en) Urinary tract infection biomarkers
Lee et al. S100 calcium-binding protein A9, a potential novel diagnostic biomarker for idiopathic pulmonary fibrosis
CN115819548B (zh) 一种检测炎症相关疾病的标志物和方法
US10830774B2 (en) Methods and compositions for diagnosis and treatment of meningitis
JP5876673B2 (ja) 精神障害の診断方法および診断薬キット
US9678084B2 (en) Compositions and methods related to S100A12
KR102132964B1 (ko) 쯔쯔가무시균 유래 엑소좀을 이용한 쯔쯔가무시병의 진단방법
EP3371331A1 (en) Detection of serum anti-fada antibodies and related diagnostic methods
US20250283894A1 (en) Ptx3 biomarker for reducing antibiotic treatment in newborns
EP1746420A1 (en) Method of rapidly and easily detecting target substance and enzymoimmunological kit
Ramezani A Rapid Differential Diagnostic Method for Detection of Post-Neurosurgical Infections
KR100733695B1 (ko) 만성염증성기도질환의 예방, 치료 및 진단용 조성물
CN107022028A (zh) 特异性抗CitH3单克隆抗体及其酶联免疫吸附试验试剂盒在脓毒症诊断中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140815

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160222

R150 Certificate of patent or registration of utility model

Ref document number: 5891230

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250